Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Simvastatin
Drug ID BADD_D02026
Description Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Simvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world.[A181084] Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%.[A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as simvastatin are thought to enter endothelial cells by passive diffusion, as opposed to hydrophilic statins such as [pravastatin] and [rosuvastatin] which are taken up into hepatocytes through OATP1B1 (organic anion transporter protein 1B1)-mediated transport.[A181424,A181460] Despite these differences in potency, several trials have demonstrated only minimal differences in terms of clinical outcomes between statins.[A181438, A181427]
Indications and Usage Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).[F4655, F4658] This includes the treatment of primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial), mixed dyslipidemia (Fredrickson type IIb), hypertriglyceridemia (Fredrickson type IV hyperlipidemia), primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia), homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).[F4655, F4658] Simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures. It is primarily used in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.[F4655, F4658] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
Marketing Status approved
ATC Code C10AA01
DrugBank ID DB00641
KEGG ID D00434
MeSH ID D019821
PubChem ID 54454
TTD Drug ID D0H0ND
NDC Product Code 78206-182; 65372-1107; 68554-0099; 16729-005; 29273-402; 42571-040; 42658-110; 42658-111; 43063-162; 61919-446; 61919-764; 63187-191; 63629-3408; 68071-4996; 68180-464; 68180-481; 68788-8369; 70377-001; 70518-3678; 71335-9642; 72789-304; 72789-320; 51846-1021; 65727-002; 65862-050; 42658-108; 50090-4736; 60687-210; 61919-688; 63629-1196; 65841-069; 65862-054; 68180-482; 70518-3349; 71335-2147; 71610-615; 72789-316; 13403-201; 58623-0125; 60312-0735; 65862-051; 16729-006; 42708-169; 55111-268; 63629-7421; 65841-066; 68071-2560; 68180-478; 68382-067; 68382-069; 68788-8406; 68788-9869; 70518-0064; 71610-050; 71610-623; 72189-427; 55154-8136; 60760-005; 63739-571; 68788-8342; 70377-004; 70518-0060; 71335-9717; 73377-135; 42571-010; 50090-1277; 50090-6424; 51655-448; 53002-1527; 60760-019; 61919-431; 63187-075; 68071-2920; 68071-2957; 68645-470; 68645-527; 70518-3630; 71205-070; 71205-192; 71610-250; 71610-610; 0615-7992; 72189-421; 78206-181; 51927-0015; 65862-221; 16714-682; 16729-007; 24658-503; 43063-733; 50090-0999; 50090-6389; 51655-113; 60760-006; 60760-580; 63629-1199; 63629-3385; 63739-570; 65841-068; 67296-0750; 68382-066; 71335-1906; 60312-0740; 60312-0749; 68554-0010; 16714-681; 29273-401; 31722-512; 42571-005; 42708-148; 50090-5788; 55111-199; 63187-449; 63629-1200; 65862-052; 68071-2559; 68180-465; 70377-003; 70518-0061; 70518-1860; 71335-1905; 71610-611; 0615-7993; 0615-8056; 58623-0049; 24658-500; 24658-501; 24658-504; 31722-510; 31722-511; 31722-514; 42571-080; 50090-4901; 53002-1528; 53002-1569; 61919-710; 63629-1198; 63739-572; 65862-053; 68071-2628; 68084-511; 68084-512; 68788-9747; 71205-780; 71205-798; 71205-809; 71335-1891; 82009-012; 16714-683; 16714-684; 16729-004; 16729-156; 24658-502; 31722-513; 42571-020; 42708-168; 43063-080; 51655-387; 55111-197; 60760-579; 65841-067; 68382-068; 68788-9429; 68788-9868; 70377-005; 70518-0583; 71335-9636; 71610-609; 72189-452; 82009-013; 82009-015; 43063-726; 50090-4897; 50090-6236; 50090-6420; 50090-6459; 51655-598; 51655-643; 60760-585; 63629-1197; 63629-3392; 63629-3393; 63739-573; 65841-065; 68071-4331; 68180-479; 68180-480; 68382-065; 70377-002; 70518-3648; 70518-3650; 71335-9630; 71610-622; 78206-180; 82009-014; 82009-016; 16714-685; 42658-109; 43063-008; 43063-727; 50090-6306; 51655-459; 51655-841; 55111-198; 55111-200; 55154-4782
UNII AGG2FN16EV
Synonyms Simvastatin | Zocor | MK-733 | MK 733 | MK733 | Synvinolin
Chemical Information
Molecular Formula C25H38O5
CAS Registry Number 79902-63-9
SMILES CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Necrotising myositis15.05.05.0160.000087%Not Available
Nodular rash23.03.13.0210.000018%Not Available
Cutaneous T-cell dyscrasia23.03.03.063; 01.05.01.0200.000011%Not Available
Unmasking of previously unidentified disease08.01.03.0800.000007%Not Available
Autoimmune myositis10.04.05.010; 15.05.01.0110.000011%Not Available
Blood loss anaemia24.07.01.088; 01.03.02.0180.000007%Not Available
Carbohydrate intolerance14.02.02.004; 07.17.01.0130.000011%Not Available
Cross sensitivity reaction10.01.01.036--Not Available
Diaphragm muscle weakness22.09.02.006; 17.05.03.019; 15.05.06.0050.000011%Not Available
Dilated cardiomyopathy02.04.01.0170.000007%Not Available
Drug effective for unapproved indication12.09.02.001; 08.06.01.0370.000086%Not Available
Drug-disease interaction08.06.03.0120.000011%Not Available
Drug-genetic interaction08.06.03.0130.000120%Not Available
Eosinophilic pleural effusion22.05.02.009; 01.02.04.0230.000018%Not Available
Fixed eruption23.03.05.008; 10.01.01.037; 08.01.06.025--Not Available
Gait inability17.02.05.069; 08.01.02.0110.000069%Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.0090.000007%Not Available
Immune-mediated myositis10.02.01.088; 15.05.01.0120.000444%Not Available
Inhibitory drug interaction08.06.03.0140.000038%Not Available
Joint noise15.01.02.0120.000015%Not Available
Lichen myxoedematosus23.03.08.0160.000022%Not Available
Mitochondrial myopathy acquired15.05.05.0190.000007%Not Available
Mixed anxiety and depressive disorder19.15.01.0100.000018%Not Available
Mucosal disorder08.01.06.029--Not Available
Palmoplantar pustulosis23.03.14.011; 10.02.01.0990.000007%Not Available
Potentiating drug interaction08.06.03.0150.000040%Not Available
Primary hyperthyroidism05.02.02.010; 14.11.01.0570.000007%Not Available
Reaction to excipient10.01.01.0420.000007%Not Available
Somatic dysfunction17.05.03.021; 15.03.05.0310.000011%Not Available
Spinal stenosis15.10.04.014; 17.10.01.0310.000022%Not Available
The 20th Page    First    Pre   20 21    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene